Nationwide large survey on hepatitis B surface antigen quantification use in real-life clinical practice

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 5, 2015, Pages 557-560

  Halfon, Philippe ^a   Penaranda, Guillaume ^a   Mohamed, Sofiane ^a   Camus, Claire ^a   Khiri, Hacène ^a  

^a Laboratoire Alphabio   (France)

Author keywords

Hepatitis B surface antigen quantification; Hepatitis B virus; Hepatitis B virus viral load

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; BIOLOGICAL MARKER;

ARTICLE; CLINICAL PRACTICE; FOLLOW UP; FRANCE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEPATITIS B; HEPATITIS B SURFACE ANTIGEN QUANTIFICATION; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REIMBURSEMENT; VIRUS LOAD; BLOOD; ECONOMICS; GASTROENTEROLOGY; HETEROZYGOTE; IMMUNOLOGY; QUESTIONNAIRE; SEROLOGY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

BIOMARKERS; CARRIER STATE; FRANCE; GASTROENTEROLOGY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PRACTICE PATTERNS, PHYSICIANS'; SEROLOGIC TESTS; SURVEYS AND QUESTIONNAIRES; VIRAL LOAD;

EID: 84927138624     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000326     Document Type: Article

References (35)

1. Blumberg BS, Alter HJ, Visnich SA. 'New' antigen in leukemia sera. JAMA 1965; 191:541-546.
2. Chevaliez S. Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol 2013; 37:559-563.
3. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013; 33 (Suppl 1):125-132.
4. Buti M, Rodriguez Frias F, Esteban R. Quantification of hepatitis B virus HBsAg: clinical implications. Med Clin (Barc) 2012; 138:483-488.
5. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55:1121-1131.
6. Bae SK, Yatsuhashi H, Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, et al. Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver. Med Sci Monit 2012; 18:CR698-CR705.
7. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57:441-450.
8. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013; 48:13-21.
9. Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peginterferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol 2013; 58:713-717.
10. Gheorghita VI, Caruntu FA, Curescu M, Olaru I, Radu MN, Coltan G, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study. J Gastrointestin Liver Dis 2013; 22:27-32.
11. Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, et al. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. J Clin Virol 2013; 57:318-322.
12. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58:872-880.
13. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011; 16:1249-1257.
14. Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 2013; 56:100-105.
15. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int 2014; 34 (Suppl 1):97-107.
16. Halfon P, Penaranda G, Ouzan D. A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success. J Hepatol 2014. [Epub 13 October 2014].
17. Ouzan D, Penaranda G, Joly H, Halfon P. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta. J Hepatol 2013; 58:1258-1259.
18. Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype. Antivir Ther 2012; 17:9-17.
19. EASL. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012; 57:167-185.
20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
21. Liaw YF, Kao JH, Piratvisuth T, Lik Yuen Chan H, Chien RH, Liu C, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6:531-561.
22. EASL. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
23. INSEE, DREES. Physicians according to their specialties and practices in France in 2014. Available at: http://www.insee.fr/fr/themes/tableau.asp?reg-id =0&ref-id =NATTEF06102. [Accessed 12 January 2015].
24. Gunning H, Adachi D, Tang JW. Calibration of qualitative HBsAg assay results for quantitative HBsAg monitoring. J Clin Virol 2014; 61:305-308.
25. Lee HJ, Kim SY, Lee SM, Heo J, Kim HH, Chang CL, et al. Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients. Ann Lab Med 2012; 32:420-425.
26. Krawczyk A, Hintze C, Ackermann J, Goitowski B, Trippler M, Gruner N, et al. Clinical performance of the novel DiaSorin LIAISON(®) XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays. J Clin Virol 2014; 59:44-49.
27. Tuaillon E, Mondain AM, Nagot N, Ottomani L, Kania D, Nogue E, et al. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One 2012; 7:e32143.
28. Hadziyannis E. Quantification of HBsAg in serum: characteristics of the assays. OA Hepatology 2013; 1:1.
29. Hadziyannis E, Hadziyannis SJ. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. Expert Rev Gastroenterol Hepatol 2014; 8:185-195.
30. Martinot-Peignoux M, Marcellin P, Asselah T. Hepatitis B: clinical application of HBsAg quantification. Ann Biol Clin (Paris) 2013; 71:19-26.
31. Larsson SB, Eilard A, Malmstrom S, Hannoun C, Dhillon AP, Norkrans G, et al. HBsAg quanti fication for identification of liver disease in chronic hepatitis B virus carriers. Liver Int 2014; 34:e238-e245.
32. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011; 18:449-457.
33. Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011; 31:516-524.
34. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454-461.
35. Thibault V, Laperche S, Akhavan S, Servant-Delmas A, Belkhiri D, Roque-Afonso AM. Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. J Virol Methods 2009; 159:265-270.